Side-by-side comparison of AI visibility scores, market position, and capabilities
Cambridge biotech developing small molecules targeting "undruggable" transcription factors for FSHD and cancer; YC W20 $6.71M competing with Fulcrum Therapeutics in the rare muscle disease therapeutic space.
Altay Therapeutics is a Cambridge, Massachusetts-based biotechnology company — backed by Y Combinator (W20) with $6.71 million raised including a $3 million seed round — developing first-in-class small molecule therapeutics that target transcription factors, historically considered "undruggable" proteins due to their lack of conventional binding sites, for rare genetic diseases and oncology indications. Founded in 2019, Altay's lead programs focus on facioscapulohumeral muscular dystrophy (FSHD) — a rare, progressive muscle disease affecting 1 in 8,500 people with no approved treatments — and cancer targets where transcription factor dysregulation drives tumor growth.
Autonomous mobile robot company for warehouse automation; flexible AMR-based fulfillment systems that adapt to changing product mixes without fixed infrastructure.
Hermes Robotics is an autonomous mobile robot (AMR) and warehouse automation company developing robots and software for logistics and fulfillment operations in warehouses, distribution centers, and manufacturing facilities. The company builds ground-based autonomous robots capable of transporting goods, fulfilling orders, and navigating dynamic warehouse environments alongside human workers, with software for fleet management and warehouse orchestration.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.